Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Inventergy Global, Inc. (INVT) Signs $2.15M Common Stock Purchase Agreement to Finance Licensing Strategy

Inventergy Global, an intellectual property (IP) licensing partner, has entered into definitive agreements with several institutional investors and accredited investors who have agreed to purchase 4,673,914 shares of the company’s common stock at $0.46 per share for gross proceeds of $2.15 million. The company said it has allocated the proceeds for working capital purposes in support of its IP licensing strategies. The closing of the offering is expected to take place on or before April 7, 2015.

“We are extremely pleased by this round of funding that provides us additional resources to pursue the various deals in our current pipeline. This strengthens our ability to move those discussions along. We look forward to keeping our shareholders and prospective investors updated and are committed to becoming the leading industry standard in technology IP licensing,” Joe Beyers, chairman and CEO of Inventergy, stated in the news release.

A shelf registration statement (File No. 333-199647) relating to the securities issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement relating to the offering will be filed by Inventergy with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at

For more information visit

Posted in Inventergy Global Inc. INVT | Leave a comment

Net Element, Inc. (NETE) Posts FY14 Financial Results, Issues Strategic Plan for 2015

Net Element, a provider of global mobile payment technology solutions and value-added transactional services, today opened its books for the fiscal year ended December 31, 2014, reporting among other things an increase in annual revenues, a significant reduction in debt, and several corporate milestones.

The adjusted loss from continuing operations for the year 2014, including special items, was $6.9 million, or a loss of $0.19 per share, as compared to an adjusted loss from continuing operations of $19.4 million or a loss of $0.68 per share, for the year ended December 31, 2013. Fiscal year 2014 net revenues were $21.2 million, as compared to $18.7 for the year 2013. The company attributes the year-over-year increase primarily to an increase of $4.6 million in transaction processing revenues offset by $2.1 million of reduced Russian mobile payment processing revenues connected with the restructuring of the company’s Russian business.

Cash provided by operating activities of continuing operations was $2.3 million for 2014 compared to cash used in operating activities of $9.8 million for 2013. Positive operating cash flow for 2014 was primarily due to the $7.9 million reduction of accounts receivable and aggregator advances offset primarily by $1.3 million of increases in accounts payable and accrued expenses.

Total liabilities were $8.8 million at December 31, 2014, compared to $37.9 million at December 31, 2013. Net Element reduced its total debt by $27.7 million to $3.3 million at December 31, 2014. In the fall of 2014, the company completed a debt exchange program which eliminated $15.9 million in debt obligations. Per the terms of its convertible debt agreement, Net Element converted $11.2 million of debt to equity upon obtaining a new $10 million credit facility. Additionally, Net Element’s factoring lines were $0 at December 31, 2014, as compared to $8.5 million at December 31, 2013.

The company highlighted several milestones in 2014 and into 2015, including:

• Improved access to credit to implement strategic initiatives; secured new financing of $10 million, triggering conversion of $11 million of debt to equity
• Advanced service offering expansion by agreeing to acquire mobile payment technology innovator PayOnline
• Reorganized mobile payments business to achieve positive operating cash flow
• Positive working capital allowed self-financing of growing mobile payments business
• Migrated to proprietary billing system for mobile business operations
• Mobile payments business exceeded 1 million recurring mobile subscribers in the month of January 2015
• Eliminated $15.9 million of debt obligations through a debt-to-equity swap
• Reduced G&A expenses by $5 million, including $1 million in salaries and $2 million in professional fees
• Announced Apple Pay™ availability in company’s U.S. POS terminal network
• Enhanced board with appointment of financial services veteran William Healy and payments technology industry veteran Drew Freeman

Net Element anticipates continuing this momentum with several initiatives set for 2015, including:

• PayOnline closing and integration
• Mobile payments expansion into Middle East and India
• Expand Russia service offerings
• Creation of omni-channel, payments-as-a-service platform that can be profitably adapted to local businesses globally

Now that we have strengthened our balance sheet by eliminating most of our debt and created a restructured operational foundation, we can advance our plan to grow market share, accelerate sales and expand profitability,” Oleg Firer, Net Element CEO, stated in the news releae. “Our growing traditional and mobile technology base, our strengthened balance sheet and strategic emphasis on Small to Medium Enterprise (SME) are competitive advantages that we expect to capitalize on during 2015.”

For more information visit

Posted in Net Element Inc. NETE | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Aligned with World Health Organization’s Global Call for Scaled-Up Response to Mental Disorders

Millions of people around the world suffer from depression, which ranges from short-lived emotional responses to something as severe as suicide, positioning the mental disease as the leading cause of disability worldwide and a dire global health concern.

While recommended depression treatment options range from psychosocial support combined with antidepressant medication or psychotherapy, scientists are seeking new, rapid-acting and more effective treatments than those currently offered in the marketplace.

The World Health Organization (WHO) estimates that globally 350 million people suffer from depression, prompting the organization in 2012 to call for a comprehensive, coordinated response to metal disorders at a country level. The WHO’s Mental Health Gap Action Programme (mhGAP) aims to help countries utilize proper care, psychosocial assistance and medication to increase services for people with mental, neurological and substance abuse disorders.

Here in the states, the U.S. National Institutes of Health (NIH) has conducted clinical trials of ketamine, an FDA-approved anesthetic and adversely used street drug, as a potential antidepressant. While ketamine demonstrates the ability to rapidly alleviate symptoms of depression – compared to current treatments which can take weeks before any therapeutic benefit is achieved – widespread clinical use of ketamine is severely limited due to its high risk for abuse and behavioral impairment, hallucinogenic and schizophrenic-like side effects, and inconvenient intravenous administration in a medical center.

Still, ketamine’s astounding antidepressant benefits have motivated biopharmaceutical companies like VistaGen Therapeutics to aggressively pursue a breakthrough new generation of depression medications.

VistaGen is developing AV-101, a novel, potent and orally- active NMDA receptor (NMDAR) glycine-binding site antagonist. In preclinical studies involving the NIH, AV-101 achieved the fast-acting antidepressant effects of ketamine – but AV-101 greatly differed in that it did not induce the adverse and psychosis-like side effects associated with ketamine and other classic NMDAR channel blockers.

In mid-February 2015, VistaGen broke ground and entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the NIH. Per the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored phase 2 clinical study of AV-101 to evaluate the efficacy and safety of the drug candidate in subjects with major depressive disorder (MDD). The study is expected to begin in the first half of this year.

VistaGen isn’t leaving much room for mistakes. The company recently welcomed key opinion leader Gerard Sanacora PhD, MD, professor of Psychiatry at the Yale School of Medicine and director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will collaborate with VistaGen to focus on phase 2 and phase 3 clinical development of AV-101 in MDD.

In addition to depression, VistaGen is also pursuing applications of AV-101 for other indications involving the central nervous system, including chronic neuropathic pain, epilepsy and neurodegenerative diseases such as Parkinson’s and Huntington’s disease. The WHO’s invigorated push for a new approach to depression treatment, however, along with the NIH’s willingness to fully-sponsor the impending Phase 2 clinical study, validates VistaGen’s primary focus of advancing AV-101’s potential as a revolutionary antidepressant for the millions globally who are inadequately served by current medications.

For more information, visit

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

Net Element, Inc. (NETE) FY2014 Financial Results Call Scheduled for Tuesday

Global payments technology provider Net Element tomorrow at 2:30 p.m. ET will discuss its operating results for its fiscal year ended December 31, 2014, via conference call. Company Chief Executive Oleg Firer and Chief Financial Officer Jonathan New will lead the call to provide shareholders and interested parties with the company’s operational and financial highlights.

Interested individuals may join the call as a participant or in listen-only mode by dialing into the respective lines below five to 10 minutes prior to the scheduled conference call time.

Conference Call Information

Date: Tuesday, March 31, 2015
Time: 2:30 Eastern Time
Conference ID: 1798030

Participant Toll-Free Dial-In Number: (877) 303-9858
Participant International Dial-In Number: +1 (408) 337-0139

Listen Only Toll-Free Dial-In Number: (800) 514-8534
Listen Only International Dial-In Number: +1 (408) 940-3842

An archive of the call will be available on the investor relations section of Net Element’s website at:

Net Element is a global payments-as-a-service, technology provider with an integrated mobile and transactional services platform serving millions of emerging market clients. The company’s wholly owned subsidiary, TOT Group operates Unified Payments, a U.S.-focused transaction processing and value-added services brand; Aptito, a next generation, cloud-based point of sale payments platform; and TOT Money, a leading mobile payments service provider that has been ranked in the Top 3 mobile payments providers by Beeline, Russia’s second largest telecommunications operator.

For more information, visit

Posted in Net Element Inc. NETE | Leave a comment

New SEC Rules Provide Smaller Companies Access to Capital, Investors More Choices

Wading through investment options can be an arduous task, but the wide range of choices is exactly what makes the market swell with money-making opportunities. The U.S. Securities and Exchange Commission (SEC) has further widened the spectrum with a set of new rules designed to give smaller companies greater access to capital and, in turn, furnish investors with even more investment choices.

The new rules update and expand Regulation A, an existing exemption from registration for smaller issuers of securities, and implement Title IV of the Jumpstart Our Business Startups (JOBS) Act. The new rules, also referred to as Regulation A+, will be effective 60 days after publication in the Federal Register.

The final rules will enable smaller companies to offer and sell up to $50 million of securities in a 12-month period, subject to eligibility, disclosure and reporting requirements.

“These new rules provide an effective, workable path to raising capital that also provides strong investor protections,” SEC Chair Mary Jo White stated in the news release dated March 25. “It is important for the Commission to continue to look for ways that our rules can facilitate capital-raising by smaller companies.”

Regulation A+ provides for two tiers of offerings:

• Tier 1, for offerings of securities of up to $20 million in a 12-month period, with not more than $6 million in offers by selling security-holders that are affiliates of the issuer;
• Tier 2, for offerings of securities of up to $50 million in a 12-month period, with not more than $15 million in offers by selling security-holders that are affiliates of the issuer.

Both Tiers are subject to certain basic requirements while Tier 2 offerings are also subject to additional disclosure and ongoing reporting requirements.

The exemption would be limited to companies organized in and with their principal place of business in the United States or Canada. The exemption would not apply to businesses that:

• Are already SEC reporting companies and certain investment companies.
• Have no specific business plan or purpose or have indicated their business plan is to engage in a merger or acquisition with an unidentified company.
• Are seeking to offer and sell asset-backed securities or fractional undivided interests in oil, gas or other mineral rights.
• Have been subject to any order of the Commission under Exchange Act Section 12(j) entered within the past five years.
• Have not filed ongoing reports required by the rules during the preceding two years.
• Are disqualified under the “bad actor” disqualification rules.

For more information, read the full release here:

Posted in Small Cap News | Leave a comment

Five Prime Therapeutics, Inc. (FPRX) Takes Leadership Position with Protein Medicines for Life

Protein therapy delivers to the body what it unfortunately lacks in those who possess a variety of illnesses. It is a medical treatment that has extensive healing possibilities currently being developed in many highly visible fields such as cancer and other debilitating diseases.

Today, this medical treatment exhibits great promise for the future as it is, for the most part, still in development and exploratory stages. The concept is similar to yet also unlike gene therapy in that protein therapy delivers protein to the body in specific amounts in the way it would ordinarily present itself to assist in repairing illnesses, treat pain or remake structures. It is important to view what we know today about protein therapy in an investigational context; however researchers and scientists indeed regard it with hope, as early studies have produced numerous benefits in many cases.

Adding to the promise of protein therapy research and development is Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company that has been focusing on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes since 2001.

FPRX’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor. The antibody is in Phase Ib clinical trials aimed at the treatment of rheumatoid arthritis and in pre-IND stage for pigmented villonodular synovitis and several cancers in combination with nivolumab.

Among the company’s numerous other candidates includes its work in the area of immune-oncology. As of late, immuno-oncology has surfaced as one of the most promising and fastest growing areas of cancer research and drug development. FPRX’s protein discovery model is well-suited to identify novel targets for the development of next generation immuno-oncology therapeutics.

Five Prime’s library, made up from more than 100 different human tissues, comprises more than 5,700 structurally complete and biologically active human proteins. The company feels this represents all of the body’s medically important targets for protein therapeutics and is a deep source of potential future protein drugs. Five Prime’s proprietary screening technology enables it to identify ligand and receptor pairs, which is necessary for the treatment of certain diseases at the highest levels.

Five Prime Therapeutics’ exciting progress does not come without pursuit and execution of collaborative agreements with industry leaders. It has a license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company and UCB Pharma S.A. Other efforts are made possible with license agreements with Galaxy Biotech LLC, The Regents of the University of California, BioWa, Inc., The Board of Trustees of Leland Stanford Junior University, National Research Council of Canada and Lonza Sales AG.

For more information on the company, visit

Posted in Small Cap News | Leave a comment

Inventergy Global, Inc. (INVT) CEO & Chairman will be Presenting at IPBC Global 2015

Today before the opening bell, Inventergy Global announced that its CEO, Chairman and Founder, Joe Beyers, will be one of the speakers at the IPBC Global 2015, presented by Intellectual Asset Magazine (see Mr. Beyers will be discusing how to build and maintain a successful licensing-based company, including:

• Understanding the challenges of the licensing landscape
• Building a robust IP portfolio
• Providing insight on new IP related business models

According to the organizers, “IPBC Global is the world’s pre-eminent gathering of senior IP business decision makers. Drawing on the large community of thought leaders based in San Francisco and Silicon Valley, as well those from further afield in the United States and abroad, the 2015 event will offer unrivalled opportunities to discuss cutting-edge issues and network with the people who make the IP weather.”

For more information on Inventergy, an intellectual property (IP) licensing partner specializing in IP value creation, visit

Posted in Inventergy Global Inc. INVT | Leave a comment

ENGlobal Corp. (ENG) – Extending Its Reach

ENGlobal provides energy-related engineering and automation services throughout the United States and worldwide. The corporation operates through two business segments – Automation and Engineering – as follows:

- The automation division provides design-, fabrication- and implementation-related services for cutting-edge automation, control, instrumentation and process analytical systems.

- The engineering division provides consulting services for the development, management and execution of projects calling for expert engineering, construction management and associated services. Within this division, ENGlobal also houses its government services group which provides for the management of various government, public sector and international facilities and systems.

Early in March 2015, ENGlobal confirmed the extension of its professional services agreement with Xcel Energy by another five years. Now that this agreement is in place, ENGlobal is expected to continue its ongoing work in all of Xcel Energy’s operating regions, including Colorado, Michigan, Minnesota, New Mexico, North Dakota, South Dakota, Texas and Wisconsin.

Xcel Energy is a major electric and natural gas company. The Minnesota-based company, whose annual revenues are in the $10.9 billion ballpark, delivers a broad portfolio of energy-related products and services to approximately 3.5 million electricity customers and 1.9 million natural gas customers via four operating companies.

ENGlobal and Xcel Energy have an established history of effective collaboration. The two companies have previously united to manage and execute several major capital programs, including the work done on a 60-mile West Main segment pipeline replacement and a 34-mile Cherokee Clean Air – Clean Jobs Act pipeline. They have also collaborated on smaller capital and maintenance jobs like those performed on Xcel Energy’s local gas transmission and distribution network.

ENGlobal anticipates using its Broomfield, Colorado office primarily to support future work on Xcel Energy’s natural gas pipeline and facility projects. The Colorado office is properly staffed with a growing team of project execution professionals who are dedicated to the midstream and downstream energy sectors.

For more information, visit

Posted in ENGlobal Corp. ENG | Leave a comment

RESAAS Services, Inc. (RSASF) Ushers Modern Social Networking Strategy into Real Estate Industry

The agile convergence of social media and both the personal and business worlds has underhandedly made every user – whether individual, group or organization – a marketer in their own right. This marketing capability has resulted in the creation of ancillary social platforms fields that heavily rely on networking, content creation and knowledge sharing. RESAAS Services, Inc., for example, is a social network structured as an agent-powered real estate industry platform that connects agents and brokers with other like-minded professionals around the world as a tool to gain referral business, attract leads and increase market exposure.

An overwhelming majority of home searches are now conducted online, creating both obstacles and opportunities for agents and brokers looking to grow their business. Traditional forms of attracting homeowners – such as billboards, public benches, newspaper advertising, etc. – are still existent, but typically generate minimal performance and results compared to modern marketing strategies that incorporate the Internet. As such, successful real estate requires agents and brokers to cater to the digital consumer and remain visible and easily accessible to potential clients.

RESAAS founder and CEO Cory Brandolini gained significant networking savvy through 25 years as a commission salesman and more than five years ago set out to use that knowledge to build a platform that would enable like-minded professionals to network online in an unprecedented manner. Incorporated in 2009, RESAAS stands as a first-of-its-kind platform for the real estate industry and now trades on the Canadian Securities Exchange (CSE) under the ticker symbol “RSS” and the OTC Market Group’s OTCQX marketplace under ticker symbol “RSASF.”

“When we look at it on the overall landscape, we’re really in an island on our own on what we’re trying to do. There are other services out there that have similar-type micro-products that that might have a crossover, but really we’re completely on our own in this space,” Brandolini states in an investor-geared corporate video.

View the video in its entirety here:

Following its commercial launch in 2013, the platform experienced exponential growth, initially tracking user signups on a daily basis – today the company gauges sign-ups per minute. Set in gear for sustainable growth, RESAAS in 2014 turned its focus on creating an industry platform inclusive of third parties, associations and vendors who would enhance industry content and contributions.

The popularity of the platform lies in its ability to address the changing temperament of today’s real estate environment by enabling real estate professionals to build a marketable social profile page, upload and browse listings, share content and information, and ask and answer questions with other industry professionals. The platform is synchronized with Facebook, Twitter and LinkedIn so the user gets more eyes on their inventory and stays connected with agents and brokers around the world.

In essence, RESAAS has harnessed the business-centered power of social media and now channels its momentum toward empowering real estate professionals as content creators and personal and business marketers with a global reach.

For more information, visit

Posted in Small Cap News | Leave a comment

Fate Therapeutics, Inc. (FATE) on Course to Address Hematologic Malignancies with PROHEMA®

It’s nearly impossible to list all the ways in which stem cell exploration is important because the usefulness of these cells is virtually limitless. Stem cells have the potential to treat a huge range of diseases and conditions that millions of people around the world suffer from. Their ability to treat so many diseases rests on their unique properties of self-renewal, differentiation and their unspecialized nature.

Fate Therapeutics (NASDAQ: FATE), San Diego, California, is a clinical-stage biopharmaceutical company with a focus on the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. It is widely known that adult stem cells play a key role in the growth, maintenance and repair of many tissues and organ systems in the body. As a result of their natural ability to self-renew, and to regenerate and repair diseased or damaged tissue, adult stem cells possess exciting prospects for a myriad of promising applications.

FATE uses the proven pharmacologic modalities of small molecules and targets well-characterized biological mechanisms to program the fate and enhance the therapeutic potential of adult stem cells. The company’s primary product candidate, PROHEMA®, is an ex vivo programmed hematopoietic cellular therapeutic. Today, PROHEMA is in clinical development for patients undergoing hematopoietic stem cell transplantation for the treatment of hematologic malignancies and certain rare genetic disorders. Integral to the company’s focus is the application of its reprogramming modulators to develop human induced pluripotent stem cell-derived cellular therapeutics, and evaluating the in vivo programming of muscle satellite stem cells using its Wnt7a-based protein analogs for muscle regeneration.

The company’s therapeutic programs target innovative mechanisms and are designed to seek out diseases with high degrees of unmet clinical need. As a result of this focus, FATE realizes that it can benefit by working with other companies who bring new ideas and experiences to the drug development market. For this reason, FATE is open to collaborating with potential partners who share its values and drive to advance stem cell science and move closer to developing therapeutics that will ultimately deliver much needed health benefits to those who need them most.

For more information on the company, visit

Posted in Small Cap News | Leave a comment